UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A0687 - Flow rate and symptom improvements maintained long-term after treatment with Optilume BPH

European urology, 2024-03, Vol.85, p.S1641-S1641

Kaplan, S.A.

2024

Volltextzugriff (PDF)

Flow rate and symptom improvements maintained long-term after treatment with Optilume BPH

European urology, 2024-03, Vol.85, p.S1641

Kaplan, S.A.

2024

Volltextzugriff (PDF)

A0242 - The pinnacle trial: 12-month report from a randomized, double-blind, sham controlled study

European urology, 2023-02, Vol.83, p.S341-S342

Kaplan, S.A.

2023

Volltextzugriff (PDF)

The pinnacle trial: 12-month report from a randomized, double-blind, sham controlled study

European urology, 2023-02, Vol.83, p.S341-S342

Kaplan, S.A.

2023

Volltextzugriff (PDF)

A0811 - Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: A US healthcare claims analysis

European urology, 2024-03, Vol.85, p.S1812-S1813

2024

Volltextzugriff (PDF)

Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: A US healthcare claims analysis

European urology, 2024-03, Vol.85, p.S1812-S1813

2024

Volltextzugriff (PDF)

Aquablation: Multi-Pass Impact

European urology, 2022-02, Vol.81, p.S1315

2022

Volltextzugriff (PDF)

De Novo BPH prescription rates are higher after TURP and PVP compared to PUL: A US healthcare claims analysis

European urology, 2022-02, Vol.81, p.S1068-S1069

2022

Volltextzugriff (PDF)

EVEREST-I: One year optilume™ BPH catheter system efficacy and safety experience

European urology open science (Online), 2020-07, Vol.19, p.e393-e394

2020

Volltextzugriff (PDF)

A0164 - Aquablation at 4-years: The largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

European urology, 2024-03, Vol.85, p.S900-S900

2024

Volltextzugriff (PDF)

Aquablation at 4-years: The largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

European urology, 2024-03, Vol.85, p.S900

2024

Volltextzugriff (PDF)

MP35-03 LOWER URINARY TRACT SYMPTOMS AS RISK FACTOR FOR CARDIOVASCULAR EVENTS IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FIVE LONGITUDINAL TRIALS

The Journal of urology, 2016-04, Vol.195 (4), p.e480-e480

2016

Volltextzugriff (PDF)

A0035 - The Impact of BPH Care: Procedural complications associated with MIST and traditional surgery compared to disease progression with medical therapy

European urology, 2023-02, Vol.83, p.S53-S54

2023

Volltextzugriff (PDF)

The Impact of BPH Care: Procedural complications associated with MIST and traditional surgery compared to disease progression with medical therapy

European urology, 2023-02, Vol.83, p.S53-S54

2023

Volltextzugriff (PDF)

174: Effect of a Process Improvement Intervention on Inpatient Telemetry Utilization Initiated In the Emergency Department

Annals of emergency medicine, 2010, Vol.56 (3), p.S58-S58

2010

Volltextzugriff (PDF)

A0244 - Everest: The peak of MIST flow rate performance?

European urology, 2023-02, Vol.83, p.S344-S345

2023

Volltextzugriff (PDF)

Everest: The peak of MIST flow rate performance?

European urology, 2023-02, Vol.83, p.S344-S345

2023

Volltextzugriff (PDF)

Functional improvement and preservation of sexual function 3 years after treatment with the optilume BPH catheter system

European urology, 2022-02, Vol.81, p.S1083-S1084

2022

Volltextzugriff (PDF)

POD-11.02: Improvements in incontinence and urgency are associated with reduced symptom bother and improved health-related quality of life

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.35-36

2007

Volltextzugriff (PDF)

POD-06.03: Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over a wide range of baseline prostate size: data from MTOPS and PLESS

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.19-20

2007

Volltextzugriff (PDF)

MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.158-159

2007

Volltextzugriff (PDF)

MP-20.23: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of serum prostate-specific antigen (PSA) level

Urology (Ridgewood, N.J.), 2007, Vol.70 (3), p.157-158

2007

Volltextzugriff (PDF)

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

Prostate cancer and prostatic diseases, 2011-06, Vol.14 (2), p.143-148

2011

Volltextzugriff (PDF)

Seismic works in Domanik-type formations exploration and prospecting

Geologiya Nefti i Gaza = Oil and Gas Geology, 2020-08 (4), p.65-81

2020

Volltextzugriff (PDF)

Introduction: BPH and sexual dysfunction - recommendations for the primary care physician and urologist

International journal of impotence research, 2008-12, Vol.20 (S3), p.S1-S1

Kaplan, S A

2008

Volltextzugriff (PDF)

1 – 25 von 145

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(136)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(143)
Tagungsberichte
(2)

Sprache

Englisch
(144)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A0687 - Flow rate and symptom improvements maintained long-term after treatment with Optilume BPH

Flow rate and symptom improvements maintained long-term after treatment with Optilume BPH

A0242 - The pinnacle trial: 12-month report from a randomized, double-blind, sham controlled study

The pinnacle trial: 12-month report from a randomized, double-blind, sham controlled study

A0811 - Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: A US healthcare claims analysis

Post-surgery medication usage through 5 years is similar between PUL, TURP and GreenLight: A US healthcare claims analysis

Aquablation: Multi-Pass Impact

De Novo BPH prescription rates are higher after TURP and PVP compared to PUL: A US healthcare claims analysis

EVEREST-I: One year optilume™ BPH catheter system efficacy and safety experience

A0164 - Aquablation at 4-years: The largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

Aquablation at 4-years: The largest, real world, single-center study and longest follow-up data for this innovative BPH treatment

MP35-03 LOWER URINARY TRACT SYMPTOMS AS RISK FACTOR FOR CARDIOVASCULAR EVENTS IN MEN: A SYSTEMATIC REVIEW AND META-ANALYSIS OF FIVE LONGITUDINAL TRIALS

A0035 - The Impact of BPH Care: Procedural complications associated with MIST and traditional surgery compared to disease progression with medical therapy

The Impact of BPH Care: Procedural complications associated with MIST and traditional surgery compared to disease progression with medical therapy

174: Effect of a Process Improvement Intervention on Inpatient Telemetry Utilization Initiated In the Emergency Department

A0244 - Everest: The peak of MIST flow rate performance?

Everest: The peak of MIST flow rate performance?

Functional improvement and preservation of sexual function 3 years after treatment with the optilume BPH catheter system

POD-11.02: Improvements in incontinence and urgency are associated with reduced symptom bother and improved health-related quality of life

POD-06.03: Long-term treatment with finasteride results in a clinically significant reduction in total prostate volume compared to placebo over a wide range of baseline prostate size: data from MTOPS and PLESS

MP-20.24: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of prostate size

MP-20.23: Tolterodine extended release (TER) and/or Tamsulosin (TAM) in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB): effects of serum prostate-specific antigen (PSA) level

Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

Seismic works in Domanik-type formations exploration and prospecting

Introduction: BPH and sexual dysfunction - recommendations for the primary care physician and urologist

Suchergebnisse filtern